A phase 1 study of radiolabeled monoclonal antibody 7E11-C5.3(177Lu-meO-DOTA-7E11;CYT-500) [Monoclonal antibody 7E11 Lu 177] in patients with progressive androgen-independent prostate cancer

Trial Profile

A phase 1 study of radiolabeled monoclonal antibody 7E11-C5.3(177Lu-meO-DOTA-7E11;CYT-500) [Monoclonal antibody 7E11 Lu 177] in patients with progressive androgen-independent prostate cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs CYT 500-Lu-177 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Cytogen Corporation
  • Most Recent Events

    • 02 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top